Advanced Solid Tumors With MAPK Pathway Mutations Clinical Trials in Wuhan, Hubei

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations